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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness of PAAPs for adults with asthma, either alone or in combination with education on self management.
B A C K G R O U N D
Description of the condition
Asthma is a common respiratory condition characterised by air-
way inflammation and oedema, bronchoconstriction and airflow
limitation. World Health Organization (WHO) estimates suggest
that up to 334 million people are affected worldwide, with the
majority of people affected in low- and middle-income countries
(Global Asthma Report 2014); the total burden may be greater
than reported due to the high prevalence of asthma in these coun-
tries that lack adequate reportingmechanisms. The economic bur-
den of asthma is considerable, with direct treatment costs and in-
direct costs of lost productivity among the highest for non-com-
municable diseases (Global Asthma Report 2014). Symptoms in-
cluding cough and breathlessness may be intermittent or persis-
tent (BTS/SIGN 2014). Triggers may be allergic (e.g. pollen, an-
imal dander, dust mite) or non-allergic (e.g. exercise, smoking,
cold air, smoke from fires in confined living spaces). The disease
may also be characterised by repeated exacerbations requiring a
change to normal maintenance therapy. Treatment of asthma in-
cludes avoidance of potential triggers (where possible), use of in-
haled corticosteroids (ICS) and leukotriene receptor antagonists
(LTRA) to reduce airway inflammation, and use of inhaled long-
acting beta2-agonists (LABA), short-acting beta2-agonists (SABA)
and anti-cholinergic bronchodilators (i.e. long-acting muscarinic
antagonists (LAMAs)) to relieve airflow limitation (BTS/SIGN
2014; GINA 2015; NICE 2007; NICE 2013). Exacerbations may
require the addition of oral or parenteral steroids. People with se-
vere asthma may also benefit from immunomodulatory therapy
targeted to key mediators of allergic airway inflammation, includ-
ing immunoglobulin E (IgE) (Normansell 2014).
The goals of asthma treatment are total control of daytime and
nocturnal symptoms, normal exercise and functional capacity, and
the preventionof exacerbations (GINA 2015). It is clear from stud-
ies including the national review of UK asthma deaths (NRAD
2014) that there remains a widespread misunderstanding, by both
patients and healthcare professionals, of appropriate asthma treat-
1Personalised asthma action plans for adults with asthma (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ment; this puts people at risk of potentially avoidable adverse out-
comes. A key recommendation to enhance asthma care is to em-
power each person to take control of their own condition, and to
equip them to deal with deteriorating symptoms early and appro-
priately (BTS/SIGN 2014).
Therefore, an important concept in asthma management is a per-
sonalised asthma action plan (PAAP) for each person. This plan
should detail the person’s baseline characteristics, including mea-
sures of airflow limitation in adults (e.g. peak expiratory flow
(PEF)) and state the agreed maintenance medication. Such plans
also provide clear instruction on how a person should respond to
increasing symptoms, with the aim of improving overall asthma
control and minimising the risk of exacerbations.
Description of the intervention
Historically, asthma action plans have been referred to using var-
ious terms including written action plans, individualised action
plans and self management action plans (Bhogal 2006). As op-
posed to a discrete intervention (Toelle 2011), PAAPs are con-
sidered an essential component of multi-faceted, self manage-
ment education (Bhogal 2006; BTS/SIGN 2014; GINA 2015;
NICE 2013). Though the format and design of action plans
vary (Charlton 1990; D’Souza 1996; Ducharme 2008; Jenkinson
1988; Kristiansen 2012; Marcano Belisario 2013; Turner 1998),
they are inherently similar in that they convey individualised self
management instructions to enable people to both attain control
of asthma and regain control in the event of an acute exacerba-
tion (Bhogal 2006). In adults, PAAPs may be based on symptoms
or peak flow monitoring, or both, whereas symptom-based plans
are generally preferable for children (BTS/SIGN 2014). Typically,
content includes objective cues to promote early detection of de-
teriorating asthma symptoms, medications prescribed and action
to take in the event of an acute episode, with particular reference
to step-up and step-down of therapy, and health service access
(Gibson 2004; Holt 2004; Partridge 2004; Toelle 2011). In prin-
ciple, individuals are not passive recipients of PAAPs (NICE 2013)
as a participatory process is intended to maximise engagement and
ensure tailoring to a person’s experience of asthma (Bauman 2003;
Gibson 1995; Lahdensuo 1999; Ring 2011). PAAPs should be
firmly embedded within the regular review process (BTS/SIGN
2014), to record the agreements made between clinician and pa-
tient. The modifiable nature of PAAPs is intended to avoid ’pre-
scribing’ of static care plans and ensure the co-production of con-
temporary self care advice in the context of the individual (Douglas
2002). In the present review, we will focus on written PAAPs.
How the intervention might work
PAAPs primarily serve to increase self management of asthma by
reminding people of their treatment plan and offering the follow-
ing directives: which triggers to avoid, when to increase treatment,
how to increase treatment, how long to increase treatment and
when to seek medical help (Gibson 2004). By promoting and in-
creasing self management of asthma, PAAPs ultimately aim to im-
prove a person’s overall control of their asthma symptoms. PAAPs
also function as an important communication tool for patients and
healthcare professionals, representing both a record and reminder
of discussions between patient and clinician (Bhogal 2006; Welsh
2011). They are individualised, enabling the underlying nature of
the person’s asthma to be taken into consideration and reviewed
on at least an annual basis (BTS/SIGN 2014).
Why it is important to do this review
The national review of UK asthma deaths highlighted that there
remain significant levels of avoidable morbidity (e.g. exacerbations
requiring oral steroids or admission to hospital) and deaths from
asthma (NRAD 2014). PAAPs are associated with better asthma
control, helping to reduce the risk of catastrophic deterioration.
For people who have had a recent acute exacerbation resulting
in admission to hospital, PAAPs may reduce re-admission rates
(NICE 2013). Although both the Global Initiative for Asthma
(GINA;GINA2015) andBritish Thoracic Society (BTS)/Scottish
Intercollegiate Guidelines (SIGN) (BTS/SIGN 2014) guidelines
recommend that people are offered self management education,
which should include a written PAAP, these recommendations are
based on evidence from over a decade ago (Gibson 2004). More-
over, the BTS/SIGN guidelines identify gaps in the evidence on
which the guidelines were based. For example, there are insuffi-
cient data to evaluate the effectiveness of certain specific compo-
nents of written PAAPs relating to corticosteroid use (BTS/SIGN
2014). Furthermore, there remains debate as to the effectiveness
of written PAAPs in specific clinical settings (Khan 2014; Sheares
2015), or when used alone or alongside education on self manage-
ment (Toelle 2011). Therefore, it is important to re-evaluate the
evidence for the effectiveness of PAAPs systematically to ensure
that the guidelines accurately reflect an up-to-date evidence base.
As PAAPs represent one component of a multi-faceted self man-
agement education, and the provision of health education gener-
ally represents a significant cost for hospitals and clinics, it is also
important to confirm the effectiveness of PAAPs plus education to
ensure the efficient use of limited resources. Finally, as the use of a
single combined LABA and ICS inhaler for both prevention and
relief of asthma symptoms has been shown to be beneficial (Cates
2013; Kew 2013), it is important to examine whether the use of
single inhaler therapy is a potential effect modifier for PAAPs.
O B J E C T I V E S
To evaluate the effectiveness of PAAPs for adults with asthma, ei-
ther alone or in combination with education on self management.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include parallel randomised controlled trials (RCTs), both
blinded and unblinded, of any duration that evaluate written
PAAPs (for details, see Types of interventions). We will include
studies reported as full-text, published as abstract only and un-
published data.
Types of participants
We will include adults (aged 18 years or over) with asthma of
any severity. The diagnosis of asthma should be determined by
a clinician in accordance with validated national or international
guidelines (e.g. BTS/SIGN 2014; GINA 2015). Studies that do
not cite a specific guideline for diagnostic purposes should provide
adequate information to allow diagnosis by the review authors as
per one of the validated guidelines. We will exclude participants
with other respiratory co-morbidities (e.g. bronchiectasis, chronic
obstructive pulmonary disease). If the search identifies studies that
include only a subset of relevant participants, we will include them
only if the study authors can provide disaggregated data for par-
ticipants who meet the inclusion criteria.
Types of interventions
Significant variability exists in the content and format of action
plans (MacGillivray 2014). We will define PAAPs as any written
plan that 1. enables people with asthma (or their carer) to recognise
when symptoms are worse and 2. sets out actions to be taken if
asthma control deteriorates. As perGINA 2015 guidelines, PAAPs
should include specific instructions for the patient (or their carer)
about changes to reliever and controller medications, how to use
OCS if needed, and when and how to access healthcare services
(GINA 2015). Thresholds for action as defined in the plans can
be based on symptoms or peak flow. We will assess the following
comparisons:
1. PAAP alone versus no PAAP;
2. PAAP plus education intervention (defined as per GINA
2015 guidelines) versus education intervention alone.
Types of outcome measures
Primary outcomes
1. Number of participants reporting at least one exacerbation
requiring emergency department visit or hospitalisation.
2. Asthma symptom scores* (measured on a validated scale,
e.g. Asthma Control Questionnaire).
3. Adverse events (all-cause).
We selected the primary outcomes to represent an important mea-
sure of resource use, a patient-reported outcome and safety.
*If a study uses more than one scale to report the same outcome,
or if different scales are used across studies, we will analyse them
together using the standardised mean difference.
Secondary outcomes
1. Quality of life (QoL)* (measured on a validated scale, e.g.
Asthma QoL Questionnaire).
2. Number of participants reporting at least one exacerbation
requiring systemic corticosteroids.
3. Measure of respiratory function - forced expiratory volume
in one second (FEV1) or PEF.
4. Days lost from work or study.
Reporting one or more of the outcomes listed above will not be
an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will identify trials from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which the Trials Search Co-ordina-
tor maintains for the Group. The Register contains trial reports
identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and
PsycINFO, and handsearching of respiratory journals and meet-
ing abstracts (see Appendix 1 for further details). We will search
all records in the CAGR using the search strategy in Appendix 2.
We will also conduct a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO trials
portal (www.who.int/ictrp/en/). We will search all databases from
their inception to the present, and we will impose no restriction
on language of publication.
Searching other resources
We will check reference lists of all primary studies and review ar-
ticles for additional references. We will search relevant manufac-
turers’ websites for trial information.
We will search for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
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Data collection and analysis
Selection of studies
Two review authors (TG, AR) will independently screen titles and
abstracts for inclusion of all the potential studies that we identify
as a result of the search and code them as ’retrieve’ (eligible or po-
tentially eligible/unclear) or ’do not retrieve’. We will retrieve the
full-text study reports/publication and two review authors (TG,
AR) will independently screen the full-text and identify studies
for inclusion. We will identify and record reasons for the exclu-
sion of the ineligible studies. We will resolve any disagreements
through discussion or, if required, we will consult a third review
author (DE). We will identify and exclude duplicates and collate
multiple reports of the same study so that each study, rather than
each report, is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA (Pref-
ered Reporting Items for Systematic Reviews and Meta-Analyses)
flow diagram and ’Characteristics of excluded studies’ table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data that has been piloted on at least one study in the
review. Two review authors (NH, DE) will independently extract
study characteristics from included studies. We will extract the
following study characteristics.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (NH,AR)will independently extract outcome
data from included studies. We will note in the ’Characteristics
of included studies’ table if outcome data were not reported in
a usable way. We will resolve disagreements by consensus or by
involving a third review author (DE). One review author (NH)
will transfer data into Review Manager 5 (RevMan 2014). We
will double-check that data are entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (DE) will spot-check study characteristics
for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (NH,DE)will independently assess risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011). We will
resolve any disagreements by discussion or by involving another
review author (AR). We will assess the risk of bias according to the
following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the risk of bias judgements across different studies for
each of the domains listed.Wewill consider blinding separately for
different key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may be very
different from a participant-reported pain scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios and 95% con-
fidence intervals (CI). We will analyse continuous data as mean
difference or standardised mean difference and 95% CI. We will
enter data presented as a scale with a consistent direction of effect.
We will use change from baseline scores when possible.
Wewill undertakemeta-analyses onlywhere this ismeaningful (i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling to make sense).
We will provide a narrative description of skewed data reported as
medians and interquartile ranges.
When multiple trial arms are reported in a single trial, we will in-
clude only the relevant arms. If two comparisons (e.g. intervention
A versus placebo and intervention B versus placebo) are combined
in the samemeta-analysis, we will halve the control group to avoid
double-counting. If trials report outcomes at multiple time points,
we will use the end of treatment time point.
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Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of participants admitted
to hospital at least once rather than the number of admissions per
participant).
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study is identified as abstract only). Where
this is not possible, and the missing data are thought to introduce
serious bias, we will explore the impact of including such studies
in the overall assessment of results using a sensitivity analysis.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity (i.e.
I2 > 50%), we will report it and explore possible causes by per-
forming pre-specified subgroup analysis.
Assessment of reporting biases
If we are able to pool 10 ormore trials, we will create and examine a
funnel plot to explore possible small study and publication biases.
Data synthesis
We will use a random-effect model for all analyses as we expect
variation in effects due to differences in study populations and
methods. We will perform sensitivity analyses using a fixed-effect
model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using data from
all seven outcomes. We will use the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence
as it relates to the studies that contribute data to the meta-analy-
ses for the pre-specified outcomes. We will use methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
Cochrane Handbook for Systematic Reviews of Interventions using
GRADEpro software (Higgins 2011). We will justify all decisions
to downgrade or upgrade the quality of studies using footnotes
and we will make comments to aid reader’s understanding of the
review where necessary.
Subgroup analysis and investigation of heterogeneity
When possible, we plan to carry out the following subgroup anal-
yses for the primary outcomes.
1. People with recent unscheduled hospitalisation versus
people without.
2. Symptom-based versus peak flow-based PAAPs.
3. Use of single inhaler therapy (e.g. a single inhaler
containing LABA plus ICS used for both prevention and relief of
symptoms).
4. Treatment instructions individualised* using OCS only
versus not individualised by OCS only.
5. Treatment instructions individualised* using ICS versus not
individualised by ICS.
6. Treatment instructions individualised* using participant-
specific triggers versus not individualised by participant-specific
triggers.
7. Format of concurrent self management education (if
applicable; e.g. sub-analysis of the duration, format or frequency
of the education).
8. Provider of self management education (e.g. physician-led
versus nurse-led education).
*Individualisation of action plans will be determined based on
whether plan templates include blank text boxes for participant-
specific asthma treatment instructions or asthma trigger details
(MacGillivray 2014).
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses while ex-
cluding the following:
1. unpublished data (i.e. no peer-reviewed full-text paper
available);
2. studies at high risk of bias for blinding.
A C K N OW L E D G E M E N T S
The ’Background’ and ’Methods’ section of this protocol is based
on a standard template used by Cochrane Airways Group. Thank
you to Elizabeth Stovold for help with the search strategy and
to Chris Cates, Emma Welsh and Kayleigh Kew for advice and
support provided.
SeanBeggswas the Editor for this review and commented critically
on the review.
The National Institute for Health Research (NIHR) is the largest
single funder of the work carried out by the Cochrane Airways
Group. The views and opinions expressed therein are those of the
review authors and do not necessarily reflect those of the NIHR,
the National Health Service or the Department of Health.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group’s Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
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(Continued)
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society (BTS) winter meeting 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
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14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify randomised controlled trials
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
We will adapt the MEDLINE strategy and RCT filter to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the Cochrane Airways Group’s
Specialised Register (CAGR)
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Individualized Medicine
#6 MeSH DESCRIPTOR Patient Education as Topic
#7 MeSH DESCRIPTOR Self Care
#8 MeSH DESCRIPTOR Patient Care Planning Explode All
#9 PAAP:ti,ab
#10 action-plan* or action* NEXT plan*
#11 written* NEAR3 plan*
#12 management* NEAR3 plan*
#13 self-management* or self* NEXT management*
#14 self-care* or self* NEXT care*
#15 self-action*
#16 medication* NEAR3 plan*
#17 tailored*
#18 individuali*ed
#19 personali*ed
#20 individual* NEAR plan*
#21 personal* NEAR plan*
#22 pictorial* NEAR plan*
#23 care* NEAR3 plan*
#24 *treatment* NEAR3 plan*
#25 goal* NEAR3 set*
#26 therapeutic* NEAR (plan* or strategy or educat* or management)
#27 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 OR #22 or #
23 or #24 or #25 or #26
#28 #4 and #27
[In search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
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